Fecal Proteomics Solutions
Fecal proteomics provides in-depth biomarker and functional information for the study of gastrointestinal health and diseases. By analyzing stool samples, we can identify disease-related protein biomarkers and molecular pathways, which are key for early diagnosis and targeted treatment strategies. MtoZ Biolabs utilizes the latest proteomics technologies to offer efficient and accurate fecal proteomics solutions, helping you discover potential disease biomarkers and understand gut microbiome functions.
Lee, PY. et al. J Biomed Sci. 2017.
Figure 1. Applications of Human Fecal Proteomics
Services at MtoZ Biolabs
Gut microbiome metaproteomics allows for functional analysis that goes beyond traditional genomics, providing a deeper understanding of the dynamic changes and health status of the gut microbiota. The application of Data-Independent Acquisition (DIA) Mass Spectrometry enables unbiased capture and quantification of all ions, ensuring comprehensive analysis of complex samples. MtoZ Biolabs applies DIA mass spectrometry to fecal samples for precise analysis, offering profound insights into gut microbiome research.
MtoZ Biolabs provides comprehensive fecal proteomics solutions. Using advanced DIA-MS platforms, we can accurately identify and quantify proteins from fecal samples, supporting both clinical and fundamental research. Our services can efficiently detect up to 9,000 proteins per sample, with precise quantification of low-abundance proteins. In addition, we offer customized targeted proteomics analysis, providing quantification of protein panels.
Analysis Workflow
1. Sample Collection and Preparation: Stool samples are collected and processed to extract proteins and microbial content.
2. Proteomic Analysis: DIA mass spectrometry is used to identify and quantify proteins in the samples, revealing their proteomic characteristics.
3. Data Analysis and Interpretation: Advanced bioinformatics tools are applied to analyze the data, identifying key biomarkers and microbiome-related signals.
Figure 2. The Workflow of Fecal Proteomics
Service Advantages
✔ High-Precision Analysis: High-sensitivity detection of low-abundance proteins ensures accurate and reliable results.
✔ Comprehensive Coverage: Up to 9,000 proteins can be detected per sample, including trace proteins and low-abundance molecules.
✔ High Throughput: Efficient processing of large-scale clinical samples ensures the efficiency and reproducibility of the research process.
✔ Stable and Reliable: Consistent results across multiple analyses provide high-confidence data for researchers.
Case Study
Case 1: This study combined 16S rRNA sequencing with fecal proteomics (label-free quantitative mass spectrometry) to comprehensively analyze the stool microbiota of healthy and ulcerative colitis (UC) patients. The results revealed significantly elevated serine-type endopeptidase activity in UC samples. By employing a biotinylated fluorophosphonate probe for enrichment, the authors detected additional active serine hydrolases. They also evaluated database completeness and the extent of the “dark peptidome” using ComPIL and de novo peptide sequencing. Ultimately, this work identified a series of key proteins markedly enriched in the fecal proteomes of UC patients, offering crucial insights into the underlying microbial and molecular mechanisms of UC and providing a foundation for further targeted investigations.
Thuy-Boun, PS. Et al. Mol Cell Proteomics. 2022.
Figure 3. Differential Expression and Protein Network Analysis of Host and Microbial Proteins
Case 2: This multicenter case-control study integrated analyses of the fecal microbiome (16S rRNA sequencing), fecal proteomics (LC-MS/MS), and amino acid profiles (HPLC). Through a multi-omics approach, the researchers identified a noninvasive diagnostic biomarker panel that outperforms the fecal occult blood test in distinguishing patients with colorectal cancer and adenomas. The integrated data revealed multiple indicators linked to bleeding, stress, and inflammation, while suggesting decreased epithelial integrity. These new biomarkers could significantly improve early screening accuracy, reduce colorectal cancer incidence and mortality, and provide a valuable foundation for future noninvasive diagnostic and intervention strategies.
Bosch, S. et al. Gut Microbes. 2022.
Figure 4. Multi-omics Pearson Correlation Network Diagram
Sample Submission Suggestions
1️⃣ Sample Type: Fecal samples (200 mg dry weight)
2️⃣ Cell and Microbe Count: At least 1×107 cells per sample
Deliverables
1. Comprehensive Experimental Details
2. Materials, Instruments, and Methods
3. Relevant Liquid Chromatography and Mass Spectrometry Parameters
4. Mass Spectrometry Image
5. Raw Data
MtoZ Biolabs' fecal proteomics analysis service provides strong technical support for both research and clinical studies, helping to gain a deeper understanding of gastrointestinal disease mechanisms and advance early diagnosis and precision treatment. Contact us today for a free consultation and learn how we can support your research!
How to order?
